NUVB vs PFE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NUVB and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NUVB and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Nuvation Bio (NYSE: NUVB) is a San Francisco oncology company founded by David Hung, best known for previously building and selling Medivation. Its commercial anchor is IBTROZI (taletrectinib), a next-generation oral ROS1 tyrosine kinase inhibitor that received full FDA approval in June 2025 for locally advanced or metastatic ROS1-positive non-small cell lung cancer across lines of therapy. The drug is positioned against first-generation options like Pfizer's Xalkori and Roche's Rozlytrek and the newer Bristol Myers Squibb agent Augtyro, and it has been added as a preferred option in NCCN guidelines. On September 17, 2026, about four months ahead of its target date, the FDA approved a supplemental application that adds a median duration of response of 49.7 months in TKI-naive patients from the TRUST-I study, which the company calls the longest reported for an FDA-approved ROS1 TKI, with no new safety signals. Beyond IBTROZI, the pipeline includes safusidenib (a brain-penetrant IDH1 inhibitor), NUV-1511 (a drug-drug conjugate), and NUV-868 (a BET inhibitor).

Full NUVB guide

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

Full PFE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NUVB drivers: IBTROZI commercial ramp; Global partner economics.
• PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: IBTROZI targets a relatively small ROS1-positive niche, so peak sales are inherently capped and depend on diagnostic testing rates and competition from Roche's Rozlytrek and BMS's Augtyro. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NUVB if you believe its drivers more; PFE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NUVB and PFE guides.

NUVB. Reported TTM revenue is inflated by large one-time collaboration upfronts, so quarterly revenue in the $30 million range (Q2 2026) is a more conservative gauge of the commercial base. With about $661 million in cash against about $416 million of debt and a market capitalization near $1.6 billion, the valuation largely reflects expectations for future IBTROZI growth and royalty streams rather than current recurring sales. Analysts expect losses to narrow toward breakeven in 2027 (consensus EPS about -$0.01), and the average price target across 11 analysts was about $13.

PFE. Pfizer trades at about 10x forward earnings and a dividend yield near 5.8%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges rather than weak operations. Even after a 17.5% gain in 2026 the shares sit right around the 26 analysts' mean target of about $29, so the valuation now balances substantial cash generation against flat-to-lower consensus earnings.

Headline figures (approximate, October 2026): NUVB shows market cap ~$1.6B, share price (oct 16, 2026) ~$4.56, revenue (ttm) ~$170M (boosted by one-time license upfronts), q2 2026 total revenue ~$32M; PFE shows revenue (ttm) ~$63.7 billion (Q2 2026 +~2.6% YoY), operating margin ~28%, net income (ttm, gaap) ~$4.3 billion, q2 2026 adjusted eps ~$0.77 vs ~$0.68 consensus.

NUVB and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NUVB and PFE exposure against your real portfolio. It is not an investment adviser.